The US biotech firm has acquired the British retinal disorder company after news of the move broke on social media.
US biotech firm Regeneron has acquired Oxford-headquartered retinal disorder firm Oxular. Financial terms have not been disclosed.
Neither company has made a statement about the move yet, but news broke when Mark Gaffney, former chief executive of Oxular, announced the move on LinkedIn.
“I am happy to report that Oxular has been acquired by Regeneron. The ophthalmology team at Regeneron is uniquely positioned to maximise the use of Oxular’s proprietary technologies. A special thank you to all of the employees, advisors, Board members and shareholders who made this transaction possible. I wish each of you all the best in your next ventures. Upward and onward!” he wrote.
Now chief executive of Calluna Pharma, Gaffney was appointed chief executive of Oxular in September 2023.
Founded in 2014, Oxular has raised £61.2 million in three rounds of funding, most recently £29.5 million in Series B funding in March 2021. That round was led by healthcare-focused venture capital firm Forbion Capital Partners.
